Location
Sutton (Greater London)
Department
Cancer Therapeutics
Advertising Salary
Salary Range: £38,607 - £40,902 per annum
Vacancy Type
Fixed term
External Advertising End Date
25 May 2022

Key Information

Starting Salary:  Dependent on relevant Postdoctoral experience. Future progression is based on annual performance review. If the candidate has not yet been awarded their PhD, the starting salary will be at  £32,844 until the successful completion of their viva.

Duration of Contract: Fixed Term until 2 August 2023

Hours per week: 35 hours per week (Full Time)
 

Job Details

Research Lead

Professor Terence Rabbitts

Summary of Role

Chromosomal translocations are common to all human cancer types and result in aberrant protein production often involving transcription factors, such as LMO2 in T cell acute leukaemias or MYCC in Burkitt’s lymphoma. These proteins are among those considered to be hard-to-drug. Intracellular antibodies are starting points as inhibitors to block protein-protein interactions or to carry effector functions such as causing protein turnover. In this context, we have developed intracellular single domain antibodies (iDAbs) that are specific to chromosomal translocation protein targets and demonstrated the requirement for the proteins in a preclinical models (target validation). The potential to directly use engineered iDAbs as drug is huge but methods that allow for their delivery in vivo are at an early stage. The role of the successful candidate will be to join the CTIAT team in achieving the delivery objective,

We are seeking a highly motivated collaborative Postdoctoral Training Fellow for a collaborative project supervised by Prof. Terry Rabbitts into the development of various forms of nanocarrier to deliver engineered intracellular antibodies into cancer cells. Nanocarriers will be investigated to deliver mRNA cargoes and will include lipid nanoparticles functionalized to engage tumour cell surface receptors. This project aims to perfect entities that can ultimately be used to systemically deliver intracellular antibodies as drugs per se.

Key Requirements

You should possess a PhD in molecular or cell biology, or chemistry, and have an excellent track record in biomedical research and experience in working with recombinant proteins, in particular antibodies. You must also have an excellent track record with nanocarriers, such as lipid nanoparticle assembly.

The ICR has a workforce agreement stating that Postdoctoral Training Fellows can only be employed for up  to 7 years as PDTF at the ICR, providing total postdoctoral experience (including previous employment at this level elsewhere) does not exceed 10 years

 

Division Information:

Professor Terry Rabbitts’ research is focused on with new strategies using intracellular antibodies and derivates for therapy aimed at hard-to-drug chromosomal translocation gene products.

We are focused on with new strategies for therapy aimed at chromosomal translocation gene products, like LMO2 and translocation protein fusions, and hard-to-drug proteins, like mutant RAS and MYC. We are developing technologies using intracellular antibodies with warheads (such as E3 ligase for protein degradation or pro-caspases for induced cell death) together with methods to allow systemic delivery of these protein macromolecules (designated macrodrugs). Our work has also recently shown that the binding sites of singe domain intracellular antibodies to the target protein (the paratope-epitope interaction region) can used to select small molecule compounds that act as surrogates of the antibody for drug discovery.

The long term goal is creation of generic strategies for deploying intracellular antibodies are drugs per se and for using intracellular antibodies in small molecule drug discovery programmes. In particular, this work is aimed at allowing the many chromosomal translocation fusion proteins, found in blood cancers, in sarcomas and in carcinomas, to be used as drug targets in cancer treatment.

Our research is multi-disciplinary, integrating molecular and cellular biology, intracellular antibody design, chemical biology and structural biology.

We encourage all applicants to access the job pack attached for more detailed information regarding this role. You may contact Prof. Terry Rabbitts for further information by emailing terry.rabbitts@icr.ac.uk. 

About The Institute of Cancer Research

Why work for us?

As a member of staff, you'll have exclusive access to a range of staff benefits.

The ICR is committed to supporting overseas applicants applying for roles, please click here to find out further information.

The Institute of Cancer Research, London, is one of the world's most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. Further information about working at the ICR can be found here.

 

We look forward to receiving applications from all candidates, wherever in the world they are currently based. We will select those who display the potential to become, or to support, the world leading cancer researchers of the future based on their application and performance at interview. However, we particularly welcome British applicants from black and ethnic minority backgrounds, as they are under-represented within the ICR and nationwide in STEM roles.


Other jobs like this

Location
Sutton (Greater London)
Department
Cancer Therapeutics
Advertising Salary
Starting Salary: £38,607 per annum
Vacancy Type
Fixed term
External Advertising End Date
06 Jun 2022
Location
Sutton (Greater London)
Department
Cancer Therapeutics
Advertising Salary
Salary Range: £38,607 - £40,902 per annum
Vacancy Type
Fixed term
External Advertising End Date
25 May 2022
Location
Sutton (Greater London)
Department
Clinical Studies
Advertising Salary
Salary Range £49,000 - £56,000 per annum
Vacancy Type
Fixed term
External Advertising End Date
06 Jun 2022